Selecta Biosciences Enters Into Exclusive License Agreement with 3SBio to Develop Drug Candidate to Treat Gout

3SBio’s pegsiticase has shown a promising efficacy and safety profile in early clinical trials and Selecta and 3SBio plan to advance clinical studies of pegsiticase-based treatments for refractory and tophaceous gout as well as tumor lysis syndrome Selecta will combine pegsiticase with its novel immunomodulatory Synthetic Vaccine Particle (SVP™) platform to develop SEL-212, a treatment with improved efficacy and safety …